Zymeworks Inc.
HealthcareNASDAQ:ZYME · NASDAQ Global Select
-$0.09 today
Vol 0.52M · Avg 0.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-30.2%
avg -65.4%
ROIC
-30.1%
avg -37.0%
ROA
-23.4%
avg -29.1%
Analysis
ROA is currently the strongest return metric at -23.4% versus its period average of -29.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | $1.71M | — | 64 | $257,266.00 | 0.35% |
Paul Moore | Chief Scientific Officer | $998,368.00 | — | 58 | $178,000.00 | 0.24% |
Mark Hollywood | Executive VP & Chief Operating Officer | — | — | 57 | $139,033.00 | 0.19% |
Sabeen Mekan | SVP & Chief Medical Officer | — | — | 46 | $0.00 | <0.01% |
Lindsey Foulkes | SVP of Corporate Development & Strategy | — | — | — | — | — |
Paul R. Schneider | Executive VP & General Counsel | — | — | 55 | $178,000.00 | 0.24% |
Laura O'Connor | Senior VP & Chief Human Resources Officer | — | — | — | — | — |
Shrinal Inamdar | VP of Investor Relations | — | — | — | — | — |
Scott Platshon | Executive VP & Chief Business Officer | — | — | 35 | $76,000.00 | 0.10% |
Diana Papove | Vice President of Corporate Communications | — | — | — | $48,750.00 | 0.07% |
Kristin Stafford | Executive VP & CFO | — | — | 44 | $119,000.00 | 0.16% |
Bijal Desai | Senior Vice President of Finance | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$4.67M
Net Sentiment
$4.67M
Net selling
Most Active
Galbraith Kenneth
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $4.67M over the last 12 months. That adds up to net selling of $4.67M. Galbraith Kenneth was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +76.4% | +18.3% (12yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +76.4% over three years. Forward estimates point to Revenue at +18.3% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.02B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.83B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
Who manages ZYME?
Zymeworks Inc. (ZYME) lists 12 active executives. The top listed executive is Kenneth H. Galbraith, Chairman of the Board, Chief Executive Officer & President.
Are ZYME insiders buying or selling?
Recent insider activity shows net buying of $101.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.